CeY-B1

CeY-B1 (0-160 µM; 48 h) inhibits the viability of SiHa cervical cancer cells with an IC₅₀ of approximately 25 µM; it also inhibits the viability of HeLa cervical cancer cells with an IC₅₀ of 5.25 µM^[1].
CeY-B1 (10-20 µM; 48 h) inhibits the proliferation, migration and invasion of SiHa and HeLa cells^[1].
CeY-B1 (5-20 µM; 48 h) induces apoptosis in SiHa and HeLa cells, and this effect is partially mediated by the JNK pathway^[1].
CeY-B1 (20 µM) upregulates the mRNA expression of ASK1 and JNK in SiHa cervical cancer cells, and downregulates the mRNA expression of Bcl-2 and cytochrome C, suggesting that the ASK1-JNK axis is activated while anti-apoptotic signals are inhibited^[1].
CeY-B1 (10-20 µM) activates the JNK/c-Jun pathway, downregulates Bcl-2, and inhibits the PI3K/AKT pathway in SiHa cervical cancer cells; it activates the JNK/c-Jun pathway and inhibits the PI3K/AKT pathway in HeLa cervical cancer cells, thereby promoting cell apoptosis^[1].
CeY-B1 (10-20 µM; 48 h) induces S-phase cell cycle arrest in SiHa cervical cancer cells and G2/M-phase cell cycle arrest in HeLa cervical cancer cells^[1].
CeY-B1 (25.6 µM; 48 h) alters lipid metabolism in SiHa cells, specifically by inducing the accumulation of pro-apoptotic ceramides and activating the sphingolipid signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.